VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo
US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as…
Dermatology
-
-
Mass General Brigham reports results from trial of skin cancer prevention therapy
Investigators at Mass General Brigham in Massachusetts, US, have reported outcomes from a study of a new immunotherapy for skin…
-
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, for treating moderate-to-severe…
-
Minghui reports positive topline data from trial of MH004 for atopic dermatitis
Minghui Pharmaceutical has reported positive topline outcomes from the randomised Phase III trial of its pan-Jak inhibitor, MH004 (tofacitinib etocomil)…
-
Galderma’s prurigo nodularis trial of nemolizumab meets endpoints
Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with…
-
Concerto doses first subject in Phase I trial of ENS-002 for atopic dermatitis
Concerto Biosciences has dosed the first subject in a Phase I trial of the three-stain live biotherapeutic product, ENS-002, aimed…
-
Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis
Johnson & Johnson (J&J) has reported positive topline outcomes from its Phase III ICONIC-LEAD trial of oral icotrokinra (JNJ-2113) for…
-
InnoCare’s Phase II psoriasis therapy trial meets primary endpoint
InnoCare Pharma has announced that its Phase II clinical study of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for psoriasis…
-
Union plans Phase III trial for atopic dermatitis after Phase IIb win
Union Therapeutics is looking to advance its PDE4 inhibitor, orismilast, into a Phase III clinical trial for atopic dermatitis (AD)…
-
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials
AbbVie has revealed positive data from a post-hoc analysis of the Phase III Measure Up 1 and Measure Up 2…
